display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - NA - all population
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone E1609 ...
Ipilimumab (10 mg/kg) E1609 ... EORTC 18071

Study type: